Recent advances in the pharmacotherapy of schizophrenia

Harvard Review of Psychiatry

Volumn 4, Issue 5, 1997, Pages 255-271

  Borison, Richard L ^a  

^a Clinical Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; APOMORPHINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AGRANULOCYTOSIS; DRUG EFFICACY; DRUG INFORMATION; HUMAN; PREVENTION; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TARDIVE DYSKINESIA;

EID: 0031029903     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229709030552     Document Type: Review

References (138)

1. Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983;6(suppl 1):S9-26.
2. Van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984;41:1036-9.
3. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987;144:1148-53.
4. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Cambridge, England: Blackwell Scientific, 1995:546-65.
5. Kane JM. Treatment of schizophrenia. Schizophr Bull 1987; 13:133-56.
6. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
7. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE. The natural course of schizophrenia: a review of first admission studies. Schizophr Bull 1992;18:185-207.
8. Gaebel W, Pietzcker A. One-year outcome of schizophrenic patients - the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 1985;18:235-9.
9. McGlashan TH, Fenton WS. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 1993;19:71-84.
10. Wyatt RW. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-51.
11. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-26.
12. Breier A, Buchanan RW, Irish D, Carpenter WT Jr. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993;44:1145-9.
13. Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia: the rationale for a double-blind clinical trial in first-episode patients. Harvard Rev Psychiatry 1995;3:1-9.
14. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-8.
15. Goff DC. Have the serotonin-dopamine antagonists rendered traditional antipsychotic agents obsolete? Harvard Rev Psychiatry 1995;3:101-3.
16. Lindström LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand 1994;89(suppl 380):74-6.
17. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990; 40:722-47.
18. Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996;47:52-6.
19. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995;345:557-62.
20. Goldstein JM. Preclinical tests that predict clozapine-like atypical antipsychotic actions. In: Brunello N, Racagni G, Langer SZ, Mendlewicz J, eds. Critical issues in the treatment of schizophrenia. Basel: Karger, 1995:95-101.
21. Goldstein JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 1995;4:291-8.
22. Helmchen H. Clinical experience with clozapine in Germany. Psychopharmacology 1989;99(suppl):S80-3.
23. Claghorn J, Honigfeld G, Abuzzahab F Sr, Wang R, Steinbook R, Tuason V, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7: 377-8.
24. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport HM. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49:345-53.
25. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
26. Andreasen N. Modified scale for the assessment of negative symptoms. NIMH treatment strategies in schizophrenia study. Rockville, Maryland: Public Health Administration, Department of Health and Human Services, 1984.
27. Paunovic VR, Marinkovic D, Timotijevic I, Jaovic-Gasic M. Clozapine in the treatment of negative syndrome in schizophrenia: a three-year follow-up study. Presented at the 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, Japan, 1990.
28. Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment refractory schizophrenics. J Clin Psychopharmacol 1994;14:201-4.
29. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-6.
30. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995;152:827-32.
31. Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl 1994;384:95-101.
32. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36:717-25.
33. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994; 55:82-7.
34. Goldberg TE, Weinberger DR. The effects of clozapine on neurocognition: an overview. J Clin Psychiatry 1994;55:88-90.
35. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45: 789-96.
36. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994;35:8-15.
37. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-52.
38. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989;99(suppl):S47-53.
39. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10.
40. De Leon J, Verghese C, Stanilla JK, Lawrence T, Simpson GM. Treatment of polydipsia and hyponatremia in psychiatric patients: can clozapine be a new option? Neuropsychopharmacology 1995;12:133-8.
41. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;136:1550-5.
42. Meltzer HY. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven, 1992:1-13.
43. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329: 162-7.
44. Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994;39:236-8.
45. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994;44:2247-9.
46. Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry 1994;55(suppl B):153-6.
47. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302.
48. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994;55(suppl B):161-5.
49. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-90.
50. Meltzer HY. Clozapine: is another view valid? Am J Psychiatry 1995;152:821-5.
51. 2 antagonist properties. J Pharmacol Exp Ther 1988;244:685-93.
52. Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992;41:494-508.
53. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2:281-93.
54. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-13.
55. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(suppl 3):S80-8.
56. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 1993;112:299-307.
57. Goldstein JM, Snyder DH. Effects of Seroquel™, clozapine, and other putative atypical antipsychotic agents in primate models of dystonia [Abstract]. Schizophr Res 1995;15:152.
58. 2 receptors. J Pharmacol Exp Ther 1992;263:276-84.
59. Borison RL, Diamond BI, Pathiraja AP, Meibach RC. Clinical overview of risperidone. In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven, 1992:233-9.
60. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
61. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
62. Müller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992;15(suppl 1, part A):90A-1A.
63. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology 1989;99:445-9.
64. Høyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402.
65. Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:129-37.
66. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995;10:207-13.
67. Möller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245:45-9.
68. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-9.
69. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15(1 suppl 1):36S-44S.
70. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
71. 2 antagonism in schizophrenia: clinical, extrapyramidal, and neuroendocrine response in a preliminary study with risperidone (R64766). Hum Psychopharmacol 1990;5:225-31.
72. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85:295-305.
73. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-8.
74. Moore NA, Tye NC, Axton MS, Risius FC. the behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-51.
75. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
76. Fuller RW, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 1992;77:87-93.
77. Stockton ME, Rasmussen K. A comparison of olanzapine and clozapine effects on dopamine neuronal activity [Abstract]. Soc Neurosci Abstr 1993;19:383.
78. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104.
79. Beasley CM, Montgomery S, Tye NC. Olanzapine: an open-label study in schizophrenia. Presented at the 2nd International Conference on Schizophrenia, Vancouver, British Columbia, 1992.
80. Beasley CM, Tollefson G, Tye NC, et al. Olanzapine: a potential "atypical" antipsychotic agent. Presented at the 32nd annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1993.
81. Tran PV, Beasley CM, Dellva MA, Cousins LM, Gusman ST, Tollefson GD. Long-term efficacy and safety of olanzapine. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995.
82. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind fixed-dose olanzapine trial. Psychopharmacology 1996; 124:159-67.
83. Beasley CM, Tran PV, Tamura RN, Sanger TM, Tollefson GD. Olanzapine versus haloperidol: results of the multi-center international trial. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995.
84. CGI, Clinical Global Impression. In: Guy W, ed. ECDEU assessment manual for Psychopharmacology. Revised ed. Rockville, Maryland: US Department of Health, Education, and Welfare, 1976:218-22.
85. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989;155(suppl 7):59-65.
86. Street JS, Tamura RN, Sanger TM, Tollefson GD. A comparison of the incidence of long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995.
87. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
88. Skarsfeldt T, Perregaard J. Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur J Pharmacol 1990;182:613-4.
89. 1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sec 1992;89:61-9.
90. Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembol HL, Meier E, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991;22:239-50.
91. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 1992;10:25-33.
92. Targum S, Caputo K, Grebb J, Chung L, Kashkin K, Mendels J. Sertindole treatment of hospitalised schizophrenic patients. Presented at the 1st International Congress on Hormones, Brain, and Neuropsychopharmacology, Rhodes, Greece, 1993.
93. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
94. Mack R, Zborowski J, Morris D, Sebree T, Wallin B. Efficacy, safety, and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995.
95. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(suppl 212):11-9.
96. AIMS: Abnormal Involuntary Movement Scale. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Revised ed. Rockville, Maryland: US Department of Health, Education, and Welfare, 1976:534-5.
97. Daniel D, Targum S, Zimbroff D, Mack R, Zborowski J, Morris D, et al. Efficacy and safety: dose responses of three doses of sertindole and three doses of haloperidol in schizophrenic patients. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995.
98. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB, Sertindole Study Group. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-75.
99. Van Kammen D, Holgate KL, Sebree T, Zborowski J, Schmitz P, Wallin B. Two open-label studies of sertindole. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995.
100. Saller CF, Salama AL. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112:285-92.
101. Goldstein JM, Litwin LC, Sutton EB, Malick JB. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:293-8.
102. Goldstein JM. The profile of "Seroquel" in preclinical tests for antipsychotic atypicality. Presented at the 3rd International Conference on Schizophrenia, Vancouver, British Columbia, 1994.
103. 2 receptor antagonists - novel atypical antipsychotics. Schizophrenia: new developments in its understanding and treatment. Presented, at the International Business Communications Conference on Schizophrenia, London, 1992.
104. Meltzer HY. An overview of the mecfianism of action of clozapine. J Clin Psychiatry 1994;55:4,7-52.
105. 1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia: a pilot study in Java monkeys. Neuropsychopharmacology 1991;2:191-9.
106. Fabre LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17:366-78.
107. Fabre LF. A multicenter, open, pilot trial of ICI 204,636 in hospitalized patients with acute psychotic symptomatology. Presented at the 4th International Congress on Schizophrenia Research, Colorado Springs, Colorado, 1993.
108. Borison RL, Arvanitis LA, Miller BG, US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-69.
109. Hirsch S, Arvanitis LA, Miller BG, Smith A, Seroquel Study Group. A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of 'Seroquel' in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia [Abstract]. Eur Neuropsychopharmacol 1994;4(3 spec iss):384-5.
110. Hamner MB, Arvanitis LA, Miller BG, Link CGG, Hong WW. Lack of sustained elevation of plasma prolactin in schizophrenic patients treated with ICI 204,636 (Seroquel™). Presented at the 148th annual meeting of the American Psychiatric Association, Miami, Florida, 1995.
111. Hamner MB, Arvanitis LA, Miller BE, Link CGG, Hong W. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996;32:107-10.
112. Link C, Smith A, Miller B, Ryan J, Seroquel Study Group. A multicentre, double-blind controlled comparison of Seroquel and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia [Abstract]. Neuropsychopharmacology 1994;4(3 spec iss):385.
113. Fleischhacker WW, Link CG. A multicenter, double-blind, randomised comparison of dose and dose regimen of "Seroquel" in the treatment of patients with schizophrenia. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1995.
114. Arvanitis L. Seroquel (ICI 204,636), a new "atypical" antipsychotic: overview of clinical development. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1995.
115. Hong WW, Arvanitis LA. The atypical profile of Seroquel (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1995.
116. Howard HR, Prakash C, Seeger TF. Ziprasidone hydrochloride. Drugs Future 1994;19:560-3.
117. 2 receptors with atypical antipsychotic potential. Presented at the 31st annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1992.
118. i values. J Pharmacol Exp Ther 1989;251:238-46.
119. 2 antagonist activities [Abstract]. Soc Neurosci Abstr 1993;19:1623.
120. 1C receptors [Abstract]. Soc Neurosci Abstr 1993;19:599.
121. 1C sites. Eur J Pharmacol 1990; 191:93-6.
122. 2 receptors of normal human brain in vitro. Eur J Pharmacol 1987;143:279-82.
123. 1A receptors in human brain tissue. Eur J Pharmacol 1992;221:397-8.
124. Howard HR. Design and synthesis of the atypical antipsychotic agent CP-88,059. Presented at the 209th national meeting of the American Chemical Society, Chicago, Illinois, 1993.
125. 2 antagonist activities [Abstract]. Soc Neurosci Abstr 1993;19:599.
126. 11C-raclopride. Psychopharmacology 1993;112:308-14.
127. Harrigan E, Chandler LP, Ko G. Ziprasidone: a novel antipsychotic. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995.
128. Niemegeers CJ, Janssen PA. A systemic study of the pharmacological activities of dopamine antagonists. Life Sci 1979; 24:2201-15.
129. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982;51:321-9.
130. Lucki I, Nobler MS, Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 1984;228:133-9.
131. Meert TF, Niemegeers CJ, Awouters F, Janssen PA. Partial and complete blockade of 5-hydroxytryptophan (5-HTP)-induced head twitches in the rat: a study of ritanserin (R55667), risperidone (R64766), and related compounds. Drug Dev Res 1989;13:237-44.
132. Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992; 17(suppl):22-9.
133. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221:1054-7.
134. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992;17(suppl):5-11.
135. Casey DE, Gerlach J, Christensson E. Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology 1980;70:83-7.
136. Spealman RD, Katz JL. Some effects of clozapine on punished responding by mice and squirrel monkeys. J Pharmacol Exp Ther 1980;212:435-40.
137. Tye NC, Iversen SD, Green AR. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 1979;18:689-95.
138. Nielsen EB. Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 1988;94:115-8.